Literature DB >> 12682709

H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization.

Victoria A Komater1, Kaitlin E Browman, Peter Curzon, Arthur A Hancock, Michael W Decker, Gerard B Fox.   

Abstract

RATIONALE: Attention deficit hyperactivity disorder (ADHD) is currently treated with psychomotor stimulants, including methylphenidate and amphetamine. Several adverse effects are associated with these drugs, however, such as agitation and abuse. H(3) receptor antagonists are under clinical investigation for ADHD.
OBJECTIVES: To investigate the potential of thioperamide, a prototypical H(3) receptor antagonist, to enhance learning and attention while inducing no effects on locomotor stimulation and sensitization, or alterations in ACTH levels.
METHODS: Thioperamide (1, 3, 10, 30 mg/kg) was administered prior to testing in a multi-trial, inhibitory avoidance response in rat pups (five trials separated by 1 min) to evaluate attention/cognition. Locomotor sensitization and cross-sensitization was assessed following administration of methylphenidate (3 mg/kg), cocaine (10 mg/kg), or thioperamide (1, 3, 10 mg/kg).
RESULTS: Thioperamide significantly enhanced performance of the five-trial inhibitory avoidance response with efficacy similar to that previously reported for methylphenidate. Administration of amphetamine, methylphenidate and cocaine produced significant locomotor sensitization, however. In contrast, thioperamide did not induce locomotor stimulation or sensitization, nor did it cross-sensitize to the stimulant effects of amphetamine or cocaine. The repeated administration of methylphenidate significantly elevated ACTH levels, while thioperamide did not affect this neuroendocrine endpoint.
CONCLUSIONS: H(3) receptor blockade may offer a safer alternative to psychomotor stimulants for the treatment of ADHD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682709     DOI: 10.1007/s00213-003-1431-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  56 in total

1.  Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup.

Authors:  Gerard B Fox; Jia Bao Pan; Timothy A Esbenshade; Youssef L Bennani; Lawrence A Black; Ramin Faghih; Arthur A Hancock; Michael W Decker
Journal:  Behav Brain Res       Date:  2002-04-01       Impact factor: 3.332

2.  Effects of intracerebroventricular injection of alpha-fluoromethylhistidine on radial maze performance in rats.

Authors:  Z Chen; Y Sugimoto; C Kamei
Journal:  Pharmacol Biochem Behav       Date:  1999-11       Impact factor: 3.533

3.  Behavioral sensitization to amphetamine is dependent on corticosteroid receptor activation.

Authors:  J M Rivet; L Stinus; M LeMoal; P Mormède
Journal:  Brain Res       Date:  1989-09-25       Impact factor: 3.252

4.  Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats.

Authors:  P E Paulson; D M Camp; T E Robinson
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine.

Authors:  R Kuczenski; D S Segal
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

6.  Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats.

Authors:  P Blandina; M Giorgetti; L Bartolini; M Cecchi; H Timmerman; R Leurs; G Pepeu; M G Giovannini
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

7.  A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.

Authors:  W E Pelham; H R Aronoff; J K Midlam; C J Shapiro; E M Gnagy; A M Chronis; A N Onyango; G Forehand; A Nguyen; J Waxmonsky
Journal:  Pediatrics       Date:  1999-04       Impact factor: 7.124

8.  Chronic L-deprenyl treatment alters brain monoamine levels and reduces impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder.

Authors:  F Boix; S W Qiao; T Kolpus; T Sagvolden
Journal:  Behav Brain Res       Date:  1998-07       Impact factor: 3.332

9.  Behavioral sensitization: characterization of enduring changes in rotational behavior produced by intermittent injections of amphetamine in male and female rats.

Authors:  T E Robinson
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Long-term facilitation of amphetamine-induced rotational behavior and striatal dopamine release produced by a single exposure to amphetamine: sex differences.

Authors:  T E Robinson; J B Becker; S K Presty
Journal:  Brain Res       Date:  1982-12-16       Impact factor: 3.252

View more
  9 in total

Review 1.  Approaches to measuring the effects of wake-promoting drugs: a focus on cognitive function.

Authors:  Christopher J Edgar; Edward F Pace-Schott; Keith A Wesnes
Journal:  Hum Psychopharmacol       Date:  2009-07       Impact factor: 1.672

Review 2.  The histamine H3 receptor: an attractive target for the treatment of cognitive disorders.

Authors:  T A Esbenshade; K E Browman; R S Bitner; M Strakhova; M D Cowart; J D Brioni
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

Review 3.  Neuronal histamine and the memory of emotionally salient events.

Authors:  Gustavo Provensi; Maria Beatrice Passani; Alessia Costa; Ivan Izquierdo; Patrizio Blandina
Journal:  Br J Pharmacol       Date:  2018-09-18       Impact factor: 8.739

4.  Changes in the histaminergic system during vestibular compensation in the cat.

Authors:  Brahim Tighilet; Suzanne Trottier; Christiane Mourre; Michel Lacour
Journal:  J Physiol       Date:  2006-04-13       Impact factor: 5.182

5.  The Novel Pimavanserin Derivative ST-2300 with Histamine H3 Receptor Affinity Shows Reduced 5-HT2A Binding, but Maintains Antidepressant- and Anxiolytic-like Properties in Mice.

Authors:  Karthikkumar Venkatachalam; Sicheng Zhong; Mariam Dubiel; Grzegorz Satała; Bassem Sadek; Holger Stark
Journal:  Biomolecules       Date:  2022-05-10

6.  Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil.

Authors:  M Uguen; D Perrin; S Belliard; X Ligneau; P M Beardsley; J M Lecomte; J C Schwartz
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 7.  Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.

Authors:  J Steven Jacobsen; Peter Reinhart; Menelas N Pangalos
Journal:  NeuroRx       Date:  2005-10

Review 8.  Sleep disturbances, psychiatric disorders, and psychotropic drugs.

Authors:  Luc Staner
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

9.  Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse.

Authors:  Divya Vohora; Malay Bhowmik
Journal:  Front Syst Neurosci       Date:  2012-10-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.